Recombinant human bone morphogenetic protein 2-induced heterotopic ossification of the retroperitoneum, psoas muscle, pelvis and abdominal wall following lumbar spinal fusion

Skeletal Radiology

Volumn 39, Issue 5, 2010, Pages 501-504

  Shah, Raj K ^a   Moncayo, Valeria M ^b   Smitson, Robert D ^b   Pierre Jerome, Claude ^b   Terk, Michael R ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone morphogenetic protein; CT; Heterotopic ossification; Lumbar spine; RhBMP 2; Spinal fusion

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ABDOMINAL WALL; ADULT; ARTICLE; BACKACHE; BONE GRAFT; CANCER INFILTRATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HETEROTOPIC OSSIFICATION; HUMAN; INTERVERTEBRAL DISKECTOMY; LIMB WEAKNESS; MALE; MULTIPLE MYELOMA; PEDICLE SCREW; PELVIS; PRIORITY JOURNAL; PSOAS MUSCLE; RADIOGRAPHY; RETROPERITONEUM; SPINE DISEASE; SPINE FUSION; SURGICAL APPROACH;

ABDOMINAL WALL; BONE MORPHOGENETIC PROTEIN 2; HUMANS; MALE; MIDDLE AGED; MUSCULAR DISEASES; OSSIFICATION, HETEROTOPIC; PELVIS; RADIOGRAPHY, ABDOMINAL; RECOMBINANT PROTEINS; SPINAL FUSION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77952547317     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-010-0890-8     Document Type: Article

References (18)

1. McKay ME, Sandhu HS. The use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine. 2002;16S:S65-85.
2. Urist MR. Bone: formation by autoinduction. Science. 1965; 150:893-899
3. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine. 2002;16S: S40-8.
4. Sandhu HS, Anderson DG, Andersson GB, Boden SD, Damien C, Ebara S, et al. Summary statement: safety of bone morphogenetic proteins for spine fusion. Spine. 2002;27:S39.
5. Gautschi OP, Sönke PF, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg. 2007;77:626-631
6. Shahlaie K, Kim KD. Occipitocervical fusion using recombinant human bone morphogenetic protein-2. Spine. 2008;21:2361-2366
7. Dimar JR, Glassman SD, Burkus K, et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Join Surg Am. 2009;91:1377-1386
8. Burkis JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337-349
9. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine. 2007;25:2885-2890
10. Tanaka H, Nagai E, Murata H, Tsubone T, Shirakura Y, Sugiyama T, et al. Involvement of bone morphogenic protein-2 (BMP-2) in the pathological ossification process of the spinal ligament. Rheumatology. 2001;10:1163-1168
11. Brower R, Vickroy N. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. Spine. 2008;33:E653-5.
12. Andrades JA, Han B, Becerra J, Sorgente N, Hall FL, Nimni ME. A recombinant human TGF-beta1 fusion protein with collagen binding domain promotes migration, growth, and differentiation of bone marrow mesenchymal cells. Exp Cell Res. 1999;250:485-498
13. Morley JR, Smith RM, Pape HC, MacDonald DA, Trejdosiewitz LK, Giannoudis PV. Stimulation of the local femoral inflammatory response to fracture and intramedullary reaming: a preliminary study of the source of the second hit phenomenon. Bone Joint Surg Br. 2008;90:393-399
14. Boden SD, McCuaig K, Hair G, Rachine M, Titus L, Wozney JM, et al. Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro. Endocrinology. 1996;137:3401-3407
15. Medtronic Sofamor Danek. United States INFUSE ® bone graft (package insert). Memphis: Medtronic Sofamor Danek; 2009
16. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood. 2000;96:2005-2011
17. Li B. Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets. 2008;8:208-219
18. Balboni TA, Gobezie R, Mamon HJ. Heterotopic ossification: pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. Int J Radiat Oncol Biol Phys. 2006;65:1289-1299f